The MEKtrix: Decoding the Real-World Impact of Therapeutic Advances in Neurofibromatosis Type 1–Associated Plexiform Neurofibroma Management Across Pediatric and Adult Populations
Date: September 14, 2025
Time: 3:30 pm to 5:00 pm
Room: Essex A - C (Fourth Floor Level)
Track: Satellite Symposia
Session Description
The initiative will begin by identifying hallmark aspects of neurofibromatosis type 1 natural history and clinical presentation, reviewing updated diagnostic criteria, and describing the genetic etiology and complex pathophysiology that has historically made neurofibromatosis type 1–associated plexiform neurofibromas so difficult to treat. Learners will then be guided through an expert-led exploration of established clinical trial data for targeted medical therapies in the setting of neurofibromatosis type 1–associated tumors in both pediatric and adult patients, with particular emphasis on toxicity profiles and responsive strategies for anticipating, mitigating, and managing adverse events in pediatric and adult populations.
Finally, real-world patient cases will offer insights into interprofessional approaches to practical challenges in neurofibromatosis type 1, including age-appropriate patient assessment, patient/parent education and answering difficult questions, effective emotional support tactics, drug toxicity mitigation tools, and expectation management for care transitions across the lifespan, including the shift from pediatric to adult care.
Faculty
Facilitator: Angela Hirbe, MD, PhD
Speaker: Miriam A. Bornhorst, MD
Speaker: Carlos Romo, MD
Provided By: CE Concepts Healthcare Education
Learning Objectives
- Assess neuro-oncologic features of neurofibromatosis type 1, including tumor types and neurological signs, to support early recognition and inform clinical decision-making.
- Evaluate the use of MEK inhibitors in the management of neurofibromatosis type 1-associated plexiform neurofibromas in pediatric and adult patients, including team-based care to manage adverse events.
- Develop evidence-based, interprofessional care plans for pediatric and adult patients with neurofibromatosis type 1 that reflect current clinical standards and support individualized, longitudinal management.
RSVP Today!
Financial Support
This program is supported through an independent educational grant from SpringWorks Therapeutics, Inc.
Credit Information:
This session is not sponsored or programmed by the American Neurological Association (ANA). The faculty are presenting on behalf of, and are paid consultants for, Creative Educational Concepts, LLC. 1.5 hours of AMA PRA Category 1 Credit™, ANCC/ONCC, AAPA, and ABIM MOC II credit are offered. Activities will be designed to meet the requirements as CME for MIPS Improvement Activities.
Disclaimer
The ANA values the participation of our corporate partners and is supportive of the role that members of this community continue to play in our efforts to provide neurologists & neuroscientists with quality educational programs. These symposia are not part of the ANA official educational program, and the sessions and content are not endorsed by ANA.
The ANA does not provide continuing medical education (CME) credits for Satellite Symposia and assumes no responsibility for credits offered by other organizations. Accredited providers are solely responsible for the content, quality, and scientific integrity of their Satellite Symposia.